What is the waiting time to access new cancer medications in Latin America?

Smiling Cancer Patient Looking at test results

FIFARMA launches the second version of the W.A.I.T. Indicator Survey measuring the waiting time to access innovative drugs in LATAM

Pasquale Frega_LACanIMI President

Universal access to health will only be possible and sustainable if innovation is a key driver


Equitable access to cancer care and treatment, a major health challenge in Latin America


Recent posts

Building Trust and Efficiency: The New Reliance Trial in Pharmaceutical Approvals
3 Cosas Que No Sabia - Victoria Brenes, Directora Ejecutiva de FEDEFARMA
Conozca a Andrea Da Pieve, Head LATAM de Biogen